CoChat

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

Open access

Published version of a preprint

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Abstract

Metastatic colorectal cancer remains largely incurable, although in a subset of patients, survival is prolonged by new targeting agents such as anti-EGF receptor (anti-EGFR) antibodies. This disease is believed to be supported by a subpopulation of stem-like cells termed colon cancer–initiating cell (CCIC), which may also confer therapeutic resistance. However, how CCICs respond to EGFR inhibition has not been fully characterized. To explore this question, we systematically generated CCICs through spheroid cultures of patient-derived xenografts of metastatic colorectal cancer. These cultures, termed “xenospheres,” were capable of long-term self-propagation in vitro and phenocopied the original patient tumors in vivo, thus operationally defining CCICs. Xenosphere CCICs retained the genetic determinants for EGFR therapeutic response in vitro and in xenografts; like the original tumors, xenospheres harboring a mutated KRAS gene were resistant to EGFR therapy, whereas those harboring wild-type RAS pathway genes (RASwt) were sensitive. Notably, the effects of EGFR inhibition in sensitive CCICs could be counteracted by cytokines secreted by cancer-associated fibroblasts. In particular, we found that the MET receptor ligand hepatocyte growth factor (HGF) was especially active in supporting in vitro CCIC proliferation and resistance to EGFR inhibition. Ectopic production of human HGF in CCIC xenografts rendered the xenografts susceptible to MET inhibition, which sensitized the response to EGFR therapy. By showing that RASwt CCICs rely on both EGFR and MET signaling, our results offer a strong preclinical proof-of-concept for concurrent targeting of these two pathways in the clinical setting. Cancer Res; 74(6); 1857–69. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-2340-t

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 150

Metadata

Authors
Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., Perera, T., Bertotti, A., Trusolino, L., Comoglio, P. M., & Boccaccio, C.
Affiliations
  • Janssen (Belgium) (BE)
  • Authors' Affiliations: 1Institute for Cancer Research at Candiolo (IRCC), Center for Experimental Clinical Molecular Oncology; 2Department of Oncology, University of Torino, Candiolo, Torino, Italy; 3Aveo Oncology Inc., Cambridge, Massachusetts; and 4Janssen Research and Development, A Division of Janssen Pharmaceutica NV, Beerse, Belgium
Corresponding author
  • Comoglio, Paolo M.
  • Boccaccio, Carla
Venue
Cancer Research
Published
2014-03-13
Volume
74
Issue
6
Pages
1857-1869
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2148532468
Cited by
146
References
47
Citations by year
2026: 4 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 10 · 2021: 23 · 2020: 12 · 2019: 12 · 2018: 14 · 2017: 15 · 2016: 11 · 2015: 16 · 2014: 8
FWCI
8.05
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders
Fondazione Umberto Veronesi
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
C-MET signaling, EGFR inhibitors, metastatic colorectal cancer, treatment resistance, hepatocyte growth factor, cancer-associated fibroblasts, KRAS mutation, Ras signaling, patient-derived xenografts, combination therapy, MET inhibition
MeSH terms
Cetuximab, Animals, Antineoplastic Agents, Cell Survival, Colonic Neoplasms, Drug Synergism, Female, Humans, Mice, Transgenic, Tumor Cells, Cultured, Neoplastic Stem Cells, Signal Transduction, Mice, SCID, Mice, Inbred NOD, Hepatocyte Growth Factor, Spheroids, Cellular, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Tumor Burden, Cell Proliferation, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-2340-t
The paper
Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., Perera, T., Bertotti, A., Trusolino, L., Comoglio, P. M., & Boccaccio, C. (2014). MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-2340-t

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.